Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cicletanine + Magnesium in Hypertension with Diabetes
NCT02709031Phase 2Unknown
- Sponsor
- Navitas Life Sciences
- Start
- Jun 2022
- Primary completion
- Jun 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised trial of cicletanine in hypertension (HTN) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Navitas Life Sciences. Primary endpoint: Time to potassium rescue at 13 weeks. Status: unknown.
02
Drugs
cicletanine
03
Conditions
hypertension (HTN)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02709031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02709031.